Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
NCT00306904
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Macular Edema
Interventions
DRUG:
bevasiranib
Sponsor
OPKO Health, Inc.